查看文章

We read with great interest the recent article by Qian et al. that reported paxlovid as an efficacious treatment for COVID-19 patients. 1 However, the relatively high cost of paxlovid and the other currently available oral antiviral, molnupiravir, will likely curtail their access in lower-income countries. 2, 3 Therefore, as the quest to find efficacious and cost-effective therapies for COVID-19 patients is still ongoing, repurposing drugs, that are approved for other indications, to treat COVID-19 is an attractive option. A recent trial by Brennen Christina et al. 4 showed that the use of famotidine for treating mild to moderate COVID-19 patients was associated with improved recovery without any significant adverse events. However, another study by Jiandong et al. 5 reported that famotidine use is associated with a higher risk of severe COVID-19 disease. Considering the newly published studies evaluating the effectiveness of …